China Selling And Marketing Expenses vs Total Operating Expenses Analysis
| SXTC Stock | USD 0.43 0.05 10.42% |
China SXT financial indicator trend analysis is way more than just evaluating China SXT Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether China SXT Pharmaceuticals is a good investment. Please check the relationship between China SXT Selling And Marketing Expenses and its Total Operating Expenses accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Selling And Marketing Expenses vs Total Operating Expenses
Selling And Marketing Expenses vs Total Operating Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of China SXT Pharmaceuticals Selling And Marketing Expenses account and Total Operating Expenses. At this time, the significance of the direction appears to have very week relationship.
The correlation between China SXT's Selling And Marketing Expenses and Total Operating Expenses is 0.29. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of China SXT Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of China SXT's Selling And Marketing Expenses and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of China SXT Pharmaceuticals are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Selling And Marketing Expenses i.e., China SXT's Selling And Marketing Expenses and Total Operating Expenses go up and down completely randomly.
Correlation Coefficient | 0.29 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Selling And Marketing Expenses
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most indicators from China SXT's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into China SXT Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At present, China SXT's Enterprise Value Over EBITDA is projected to increase slightly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 6.50, whereas Tax Provision is forecasted to decline to 0.00.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.3M | 426.3K | 554.0K | 526.3K | Total Revenue | 2.6M | 2.0M | 1.9M | 3.5M |
China SXT fundamental ratios Correlations
Click cells to compare fundamentals
China SXT Account Relationship Matchups
High Positive Relationship
High Negative Relationship
China SXT fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 21.7M | 34.5M | 33.5M | 29.6M | 23.1M | 21.9M | |
| Other Current Liab | 3.3M | 15.7M | 12.3M | 8.5M | 4.0M | 6.5M | |
| Total Current Liabilities | 12.3M | 18.6M | 17.1M | 14.5M | 8.9M | 11.1M | |
| Total Stockholder Equity | 9.4M | 16.0M | 16.4M | 14.7M | 13.9M | 10.7M | |
| Net Tangible Assets | 11.0M | 9.4M | 15.9M | 16.4M | 18.8M | 19.8M | |
| Retained Earnings | (7.2M) | (10.0M) | (15.7M) | (21.6M) | (24.7M) | (23.5M) | |
| Accounts Payable | 1.9M | 1.5M | 1.5M | 1.4M | 1.3M | 1.4M | |
| Cash | 7.3M | 13.3M | 15.5M | 17.4M | 12.1M | 9.2M | |
| Cash And Short Term Investments | 7.3M | 13.3M | 15.5M | 17.4M | 12.1M | 9.2M | |
| Net Receivables | 10.6M | 7.8M | 4.9M | 1.3M | 1.3M | 1.3M | |
| Inventory | 892.8K | 859.7K | 1.0M | 531.3K | 809.8K | 799.6K | |
| Other Current Assets | 144.3K | 1.3M | 995.8K | 230.6K | 6.8K | 6.5K | |
| Other Stockholder Equity | 17.2M | 25.3M | 31.0M | 35.6M | 35.3M | 19.0M | |
| Total Liab | 12.3M | 18.6M | 17.1M | 14.9M | 9.2M | 11.2M | |
| Total Current Assets | 19.6M | 23.2M | 22.5M | 19.5M | 14.2M | 16.1M | |
| Short Term Debt | 6.7M | 37.1K | 2.0M | 3.4M | 2.4M | 1.9M | |
| Intangible Assets | 50.1K | 45.8K | 38.8K | 27.9K | 19.1K | 34.3K | |
| Common Stock | 34.7K | 62.1K | 162.5K | 913.8K | 4.4M | 4.6M | |
| Property Plant Equipment | 1.8M | 1.9M | 1.8M | 1.6M | 1.8M | 1.5M | |
| Short Long Term Debt Total | 6.7M | 43.4K | 2.0M | 3.8M | 2.6M | 2.2M | |
| Property Plant And Equipment Net | 1.9M | 1.8M | 1.6M | 1.3M | 564.7K | 1.1M | |
| Current Deferred Revenue | 298.0K | 257.4K | 77.4K | 165.5K | 187.7K | 192.3K | |
| Net Debt | (563.2K) | (13.3M) | (13.5M) | (13.6M) | (9.4M) | (9.9M) | |
| Non Current Assets Total | 2.1M | 11.3M | 11.1M | 10.0M | 8.9M | 6.5M | |
| Non Currrent Assets Other | 441.2K | 9.2M | 9.5M | 8.7M | 8.3M | 5.0M | |
| Common Stock Shares Outstanding | 12.4K | 28.8K | 41.6K | 267.0K | 867.4K | 910.8K | |
| Liabilities And Stockholders Equity | 21.7M | 34.5M | 33.5M | 29.6M | 23.1M | 23.8M | |
| Non Current Liabilities Total | 36.5K | 6.3K | 3.6M | 365.8K | 294.7K | 279.9K | |
| Property Plant And Equipment Gross | 1.9M | 1.8M | 3.4M | 3.2M | 3.1M | 2.4M | |
| Short Long Term Debt | 6.7M | 37.1K | 2.0M | 3.3M | 2.3M | 2.1M | |
| Accumulated Other Comprehensive Income | (590.7K) | 527.8K | 956.1K | (197.6K) | (1.0M) | (974.5K) | |
| Other Assets | 13.5K | 112.8K | 9.5M | 9.5M | 10.9M | 11.4M | |
| Net Invested Capital | 16.1M | 16.0M | 18.5M | 18.1M | 16.3M | 15.7M | |
| Net Working Capital | 7.4M | 4.7M | 5.3M | 5.0M | 5.3M | 6.1M | |
| Capital Stock | 34.7K | 62.1K | 162.5K | 913.8K | 4.4M | 4.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (3.57) | Revenue Per Share 2.223 | Quarterly Revenue Growth 0.295 | Return On Assets (0.05) |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.